The remarkable success achieved by angiotensin-converting enzyme inhibitors in the treatment of hypertension and congestive heart failure has generated considerable interest in the development of novel and selective pharmacological agents designed to intervene in the renin-angiotensin system (RAS). In the past several years there have been extraordinary advances in the development of potent nonpeptide angiotensin II (AII) receptor antagonists. (Fig. 1 ).
), 1) D-8731, 2) L-158809, 3) and A-81988 4) are examples of angiotensin II type 1 (AT 1 ) receptor selective antagonists (Fig. 1) . 5) In our previous report, 6) we described the discovery of novel nonpeptide AII receptor antagonist 7-oxo-4,7-dihydropyrazolo [1,5-a] pyrimidine-3-carboxylic acid (1) and its analogues. These derivatives showed potent in vitro activity, but no marked decrease in blood pressure was observed in spontaneously hypertensive rats (SHRs) after their oral administration. To obtain potent orally active AII antagonists, we performed the three-step transformations illustrated in Fig. 2 . First, we removed the 3-carboxylic acid and changed the heterocyclic system. Second, we designed a new heterocyclic system, pyrazolo [1,5-a] pyrimidine, considering the structures of the other existing orally active AII antagonists (such as A-81988 or D-8731) and the key features necessary for receptor binding of 5a (Fig. 3 ). This compound showed oral antihypertensive activity in the SHR model. Finally, finetuning of the substituents on the heterocycle and spacer of the heterocycle and biphenyltetrazole provided highly potent and orally active AII antagonists. Here we report the details of our design and the structure-activity relationship (SAR) studies that led to the discovery of novel AII antagonists.
Chemistry A series of azolopyrimidine heterocycles of 3a-c were readily accessible from condensation of ethyl 2-formylpentanate (2) and the corresponding aminoazole deriv-atives as shown in Chart 1. Alkylation of the resulting azolopyrimidine derivatives (3a-c) with 4-bromomethyl-2Ј-cyanobiphenyl 1) in N, N-dimethylformamide (DMF) using sodium hydride as base, followed by conversion of the cyano group to the tetrazole using trimethyltin azide gave 5a-c. Chart 2 illustrates the general route to the pyrazolo [1,5-a] pyrimidine derivatives. 3-Aminopyrazole derivatives (6a-h) were cyclized with b-keto esters (7a-d) to afford the corresponding substituted pyrazolo [1,5-a] pyrimidin-7-(4H)-ones (8a-m), which were converted to the 7-chloro derivatives (9a-m) by treatment with phosphorous oxychloride. 7) 2-Cyano-4Ј-(aminomethyl)biphenyl 8) was allowed to react with 7-chloropyrazolo [1,5-a] pyrimidines (9a-m), and the resulting cyano derivatives (10a-m) were converted to the tetrazole derivatives (11a-m) using trimethyltin azide. Preparations of 5-heteroatom-substituted derivatives (16, 19a-d ) and the unsubstituted compound (15) are presented in Chart 3. Reaction of 5,7-dichloropyrazolo[1,5-a]pyrimidine 9) (12) with 2-cyano-4Ј-(aminomethyl)biphenyl gave 13. Converting the cyano group to the tetrazole gave the 5-chloro derivative (16) . Unsubstituted compound (15) was synthesized by reduction of 13 on Pd/C, followed by conversion of the cyano group to the tetrazole. 5-Heteroatom-substituted derivatives (18a-d) were obtained by reaction of the tertbutoxycarbonyl (Boc)-protected compound (17) with various nucleophiles. After deprotection of the Boc group, the tetrazole ring was formed with trimethyltin azide in refluxing xylene. Direct biphenylmethylation of 9b and 9f was performed by coupling with zinc reagent (20) in the presence of palladium catalyst as shown in Chart 4. The regioselective crosscoupling reaction of 5,7-dichloro derivative (12) with 20 was achieved using LiCl as an additive.
10) The coupling product (23) was treated with various nucleophiles, and the cyano derivatives were converted to the tetrazole derivatives (25a-c).
Results and Discussion
All of the compounds synthesized were evaluated as AII antagonists by testing their potency to displace [ 125 I]AII binding to COS cells transfected with a cDNA encoding a human AT 1 receptor. We also tested the inhibition of [
125 I]AII binding in a rat liver membrane preparation (AT 1 receptors). The K i values calculated from IC 50 values in these assays are listed in Tables 1-3 .
Oral activity was not found in the compound 1 series due to its low bioavailability. The presence of two acidic functional groups may have been the cause of the poor absorption, 11) so we first examined whether it was possible to remove the 3-carboxyl group in 1 and replace the heteroaromatic systems (step 1 in Fig. 2 ). In this step, we tried replacing the carboxylic acid with an aromatic nitrogen atom, because there were several examples of incorporation of various hydrogen bonding groups, such as carboxyl, carbonyl or aromatic nitrogen, in heterocyclic systems leading to equal enhancement of the binding activity. 12) From the results shown in Table 1 , imidazolo [1,5-a] pyrimidine (5a) showed affinity almost comparable to the parent carboxylic acid derivative (1) . The number of nitrogen atoms in the heterocyclic system dramatically influenced the binding activity. The order of the binding activity of these com- pounds (5aϾ5bϾ5c) was related to the hydrogen bonding ability of the 5-membered ring portion (imidazoleϾtriazole Ͼtetrazole). 13) These results suggest that this nitrogen plays an important role as a hydrogen bond acceptor when binding to the receptor. Although 5a was potent in vitro, it lacked in vivo activity.
Next, we designed the pyrazolo[1,5-a]pyrimidine heterocycle, which was linked to the biphenyltetrazole moiety by an aminomethylene group such as 11b (step 2 in Fig. 2 ). As outlined in Fig. 3 , this structure was derived from incorporation of the essential features for receptor binding suggested as imidazolo [1,5-a] pyrimidine derivative 5a and the published compounds, A-81988 or D-8731, which were reported as good orally active AII antagonists. In this heterocycle, the amide group of 1, which was thought to be one of the causes of poor absorption, was removed.
Compound 11b retained its potent binding affinity (IC 50 ϭ0.31 nM) and when orally administered to SHRs, caused a moderate decrease in blood pressure. We next focused on preparing analogs of 11b for optimizing the in vitro and in vivo activities (step 3 in Fig. 2 ).
Several groups have reported the presence of two hydrophobic interactions between the AII receptor and the alkyl substituents on the heterocycle. One site is the C 5 -position of 2,4-dihydro-3H-1,2,4-triazol-3-one receptor antagonist (26 shown in Fig. 4) , which corresponds to the 2-substituent of the imidazole ring in losartan, and the other site is the N 2 -substituent of 26. 8,12c-e) We superimposed the pyrazolo[1,5-a]pyrimidine (11a) and 26 in the same manner as that reported for the superimposition of D-8731 and Dup753 (Fig.  4) .
2) As shown in Fig. 4 , the first lipophilic moiety of the 5-position of 11a corresponds to that of the 5-position of 26. This superimposition indicated that the methyl group at the N 2 -position of 26 corresponds to the hydrogen at the 3-position of 11a. Thus our modification of the pyrazolo [1,5-a] pyrimidine derivatives focused on the 3-and 5-positions.
The SARs of the 3-and 5-positions of the pyrazolo [1,5-a] pyrimidines are summarized in Table 2 . Introduction of methyl, ethyl or chloro groups into the 3-position enhanced binding activity (11f, 11h, 11l vs. 11b) . 3-Propyl or 3-ethoxycarbonyl derivatives (11i, 11m), had slightly less potency, whereas the 3-phenyl derivative (11j) showed a dramatic loss of the binding affinity.
Optimal activity at the 5-position occurred with the ethyl substituent (11b). The chloro, methyl and n-propyl compounds were less potent than ethyl derivative (16, 11a, 11c vs. 11b). Introduction of larger groups such as phenyl and dimethylamino groups decreased the binding activity (11d, 19d) and unsubstituted derivative (15) also decreased the binding activity. Electronic character of the 5-position was generally unrelated to the binding activity. Electron-donating groups, such as methoxy and ethoxy substituents, decreased the binding activity slightly, and the electron-withdrawing chloro substituent also decreased it.
We also examined the binding activity of a series of compounds with the biphenylmethyl moiety directly attached to the pyrazolo[1,5-a]pyrimidine heterocycle ( Table 3 ). The 5-ethyl compound (22a) was one of the most potent AII antagonists of the pyrazolo [1,5-a] pyrimidine series. The 3-methyl-5-ethyl derivative (22b) showed similar potency to the aminomethylene linker counterpart (11f), but was less potent than 22a. These results differed from those for aminomethylene linker derivatives (11b vs. 11f), which indicates that this series of compounds bind to the AII receptor in a different manner. The introduction of alkylhetero substituent groups at the 5-position generally led to adverse effects on receptor binding affinity (25a-c).
Selected compounds were given orally to SHR and the systolic blood pressure (SBP) was monitored. The changes of SBP after 7 h of oral dosing at 10 mg/kg are listed in Tables 2  and 3 . The in vivo activities of these compounds did not always correlate well with the in vitro binding activities. Introduction of the 3-methyl substituent led to highly potent antihypertensive active compounds (11e, 11f). The 5,7-dimethyl derivative (11e) is equipotent with losartan, and the 3-methyl-5-ethyl derivative (11f) showed the most potent in vivo activity in this study. While 11g-i, and 16 were potent AII antagonists in vitro, they were extremely weak for decreasing blood pressure in this model. Because these compounds were potent AII antagonists in rat liver membranes, their low in vivo activity might be due to their low bioavailability. Direct biphenylmethyl substituted derivatives (22a, 22b) showed antihypertensive activities but were less efficacious than losartan.
Conclusions
New orally active AII antagonists were explored with 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid derivatives as lead structures. The 3-carboxylic substituent can successfully replace the aromatic nitrogen atom with retention of in vitro activity. SAR of the series of com- 
Experimental
Molecular Modeling All calculations were performed with a Silicon Graphics Indigo 2 R4400 workstation. All molecular models were constructed with the molecular modeling software package SYBYL 6.01 and 6.10, 14) using molecular fragments and standard bond lengths and angles from the SYBYL structure library. Each structure was optimized by means of the molecular mechanics minimizer MAXIMIN2 and the standard TRIPOS force field by neglecting the electrostatic contribution. The conformations of 11a and 26 in Fig. 4 were adopted in the gauche and helix-1 conformation, respectively, by referring to the literature.
2)
AII Receptor Binding Assay Using COS Cells A cDNA encoding human AT 1 receptor, donated by Dr. T. Inagami (Vanderbilt University, Nashville, TN), was inserted into the mammalian expression vector psDNA 1 (Invitrogen). COS-7 cells plated in 175-cm 2 flasks grew to 80% confluency after 3 d. The cells were then transfected with 40 mg DNA by 150 ml of lipofectin reagent (GIBCO). Two or three days after transfection, the binding assay was done as described previously. 15) In brief, cell suspensions (1.2ϫ 10 6 cell/ml), dispersed with 0.025% trypsin/1 mM EDTA, were incubated at 25°C for 60 min in 0.2 ml of Hepes (20 ml)-buffered Hanks' solution containing 1 mg/ml phenylmethanesulfonyl fluoride (PMSF), 10 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mg/ml pepstatin A, 250 mg/ml bacitracin, 10 mg/ml soybean trypsin inhibitor, and 0.1 mM amastatin 0.1 nM [ 125 I]AII (81.4 TBq/mmol, New England Nuclear) in the absence or presence of nonradioactive peptide or drugs. Each binding reaction was terminated by addition of 2.5 ml of ice-cold 50 mM Tris-HCl (pH 7.4), followed by rapid filtration through a GF/C glass fiber filter under reduced pressure. The filters were then quickly washed four more times with 2.5 ml of the Tris buffer, and the radioactivity retained on the filters was counted. Nonspecific binding, determined in the presence of 10 Ϫ6 M nonradiolabeled AII, was 5-10% of the total binding. K i values were calculated from the equation 
AII Receptor Binding Assay Using Rat Liver Membranes
The rat liver membranes were prepared according to the method of Chiu et al. 16) The incubation mixture (0.1 ml) contained 50 mM Tris-HCl (pH 7.4), 0.1 mM amastatin, 1 mM a-PMSF, and membranes (0.03-0.05 mg of protein) with 0.2-0.3 nM [
125 I]AII in the absence or presence of non-radioactive compounds. The equilibrium binding studies were carried out according to the procedure using COS cells.
Oral Antihypertensive Activity in SHR Male SHRs, 16-18 weeks old, were used for the oral dose-response study of the acute hypotensive effect. SBP was measured by the tail-cuff method reported by our laboratory 17) at 7 h after oral administration of the test drugs.
Chemical Synthesis Unless otherwise stated, all reactions were carried out under a nitrogen atmosphere. Tetrahydrofuran (THF), ether, xylene and DMF were dried over 4 Å molecular sieves. Flash chromatography was performed on silica gel (Merck Kieselgel: Art9385). Zinc dust, Pd(Ph 3 P) 4 , and n-butyllithium in n-hexane solution were purchased from Aldrich, Inc.
6-Propyl-8H-imidazo[1,2-a]pyrimidin-5-one (3a)
To a solution of ethyl n-valerate (3.91 g, 30 mmol) and ethyl formate (4.80 g, 64.8 mmol) in THF (15 ml) at 25°C was added dropwise a solution of potassium tert-butoxide (7.50 g, 66.8 mmol) in THF (50 ml) over a period of 45 min. The resulting mixture was stirred for 3 h at room temperature and the solvent was evaporated in vacuo. The residue was dissolved in water and washed twice with ether. The resulting aqueous layer was acidified with 12 N HCl to pH 2 and extracted with three 50 ml portions of ether, and the combined extracts were dried (MgSO 4 ), and the solvent was evaporated in vacuo to give 3.82 g of crude ethyl 2-formylpentanate 2 as a yellow oil. This oil (1.9 g, 12 mmol) was dissolved in EtOH (20 ml). 2-Aminoimidazole sulfate (1.1 g, 8.4 mmol) and piperidine (1.0 ml, 10.1 mmol) were added to this solution, the resulting mixture was stirred for 2 h at room temperature, and the solvent was evaporated in vacuo. The resulting residue was partitioned between EtOAc and water. The organic layer was separated, washed with water, dried (MgSO 4 ), and the solvent was evaporated in vacuo. , 0.9 mmol) was dissolved in 2 ml of polyphosphoric acid (PPA) and the resulting solution was stirred at room temperature for 18 h. The mixture was poured into ice water, neutralized to pH 6-7 with NaOH. The solution was extracted with three 30 ml portions of CHCl 3 , the combined extracts were dried (MgSO 4 ), and the solvent was evaporated in vacuo. The residue was recrystallized from EtOAc-n-hexane to give 3c (14 mg, 1%) as colorless prisms. mp 108-110°C. 
4-[(5-Oxo-6-propyl-5H-imidazo[1,2-a]pyrimidin-8-yl)methyl]-biphenyl-2-carbonitrile (4a)
A mixture of 3a (532 mg, 3.0 mmol) and NaH (60% dispersion in mineral oil; 130 mg, 3.3 mmol) in DMF (4.5 ml) was stirred until evolution of hydrogen ceased. A solution of 4-bromomethyl-2Ј-cyanobiphenyl (817 mg, 3.0 mmol) in DMF (5 ml) was added and the mixture was stirred for 1 h at 0°C. The resultant mixture was poured into ice water and extracted with three 30 ml portions of EtOAc. The combined extracts were washed with water (20 ml) and saturated brine (20 ml) and then dried (MgSO 4 ). The solvent was evaporated in vacuo and the residue was purified by flash chromatography (CH 2 Cl 2 : CH 3 CNϭ1 : 10 as an eluent) to give 4a (589 mg, 26%; less polar product) as colorless needles. mp 135-136°C. 
6-Propyl-8-[[2-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-8H-imidazo[1,2-a]pyrimidin-5-one (5a)
A mixture of 4a (520 mg, 1.4 mmol) and trimethyltin azide (350 mg, 1.7 mmol) in xylene (6 ml) was heated under reflux for 48 h, and the solvent was evaporated in vacuo. The residue was stirred with 1 N HCl (1.5 ml) for 1 h at room temperature, neutralized to pH 8 with saturated aqueous NaHCO 3 and extracted with three 30 ml portions of CH 2 Cl 2 . The combined extracts were washed with water (20 ml) and saturated brine (20 ml) and dried (MgSO 4 7-Chloro derivatives (9) were synthesized by the literature method 7) and crude products were passed through short silica gel column chromatography and used without further purification.
1 H-NMR spectrum data are listed in 934 Vol. 47, No. 7 
General Method for the Synthesis of 4-[(Pyrazolo[1,5-a]pyrimidin-7-yl)aminomethyl]biphenyl-2-carbonitrile Derivatives (10). 4-[(5-Methylpyrazolo[1,5-a]pyrimidin-7-yl)aminomethyl]biphenyl-2-carbonitrile (10a)
A mixture of 9a (168 mg, 1 mmol), 2-cyano-4Ј-(aminomethyl)-biphenyl (208 mg, 1 mmol) and potassium carbonate (276 mg, 2.0 mg) in acetonitrile (10 ml) was stirred for 16 h at room temperature and the solvent was evaporated in vacuo. The resultant mixture was poured into ice water and extracted with three 30 ml portions of EtOAc. The combined extracts were washed with water (20 ml) and saturated brine (20 ml) and then dried (MgSO 4 ). The solvent was evaporated in vacuo and the residue was purified by flash chromatography (CH 2 Cl 2 : CH 3 CNϭ10 : 1 as an eluent) to give 10a as an amorphous powder (77% (11, 15, 16, 19, 22, 25) were synthesized according to the procedure described for 5a from corresponding cyano derivatives. Physical data are listed in Tables 5 and 6 .
4-[(5-Chloropyrazolo[1,5-a]pyrimidin-7-yl)aminomethyl]biphenyl-2-carbonitrile (13)
The title compound was prepared from 12 and 2-cyano-4Ј-(aminomethyl)biphenyl according to the procedure described in the preparation of 10a as colorless prisms. mp 152-153°C. 
4-[(Pyrazolo[1,5-a]pyrimidin-7-yl)aminomethyl]biphenyl-2-carbonitrile (14)
A mixture of 13 (210 mg, 0.58 mmol), ammonium formate (55 mg, 0.87 mmol) and 5% palladium on carbon (60 mg) in toluene (2 ml) was heated under reflux for 4 h and the mixture was filtered. The filtrate was evaporated in vacuo to give 14 (160 mg) as white crystals (85%). mp 171-172°C. 
4-[(5-Methoxypyrazolo[1,5-a]pyrimidin-7-yl)aminomethyl]biphenyl-2-carbonitrile (18a)
A solution of 17 (600 mg, 1.67 mmol) and 0.5 N NaOMe (4.68 ml, 2.34 mmol) in THF (4 ml) and MeOH (5 ml) was stirred for 1 h at 70°C. The mixture was poured into CH 2 Cl 2 , washed with water and saturated brine, and then dried (MgSO 4 ). The solvent was evaporated in vacuo and the residue was recrystallized from acetone-n-hexane to give 514 mg of Boc intermediate as white prisms (87%). mp 164-165°C. 
4-[(5-Ethylpyrazolo[1,5-a]pyrimidin-7-yl)methyl]biphenyl-2-carbonitrile (21a)
To a suspension of zinc dust (activated with 1,2-dibromoethane and chlorotrimethylsilane; 1.63 g, 25 mmol) in THF (1.5 ml) at 0°C was added dropwise a solution of 4-bromomethyl-2Ј-cyanobiphenyl (545 mg, 2 mmol) in THF (4 ml) over a period of 30 min. The resulting mixture was stirred for 1 h at 0°C, then left standing for 1 h at 0°C. The supernatant was transferred to a solution of 9b (290 mg, 1.5 mmol) and tetrakis(triphenylphosphin)palladium(0) (55 mg, 0.05 mmol) in THF (2 ml), and heated under reflux for 1 h. The mixture was poured into saturated ammonium chloride solution and ice, and extracted with three 30 ml portions of EtOAc, then combined extracts were washed with water (20 ml) and saturated brine (20 ml) and then dried (MgSO 4 ). The solvent was evaporated in vacuo and the residue was purified by flash chromatography (toluene : EtOAcϭ20 : 1 as an eluent) to give 21a (360 mg, 53%) as colorless prisms. mp 124-126°C. 1 
